Neuroblastoma exhibit an extreme clinical and biological heterogeneity, and patients are assigned to risk groups based on several criteria including stage [2,3], age [4], histological category and grade of tumour differentiation (histopathology) [5], the status of the MYCN oncogene [6], chromosome 11q status [7], and DNA ploidy [8] as the most highly statistically significant and clinically relevant factors [9]. The gene discussed is MYCN; the disease is neuroblastoma.